Optiscan Imaging is pleased to announce that it has lodged a prospectus with ASIC in respect of a pro rata entitlement offer of one (1) fully paid ordinary share for every three (3) Shares held on the record date of Friday 2 June 2023.
The funds raised under the offer will be used to:
- Further the Company’s research and development (R&D) projects specifically for both rigid and flexible surgical applications.
-Develop improved image capture, AI and telepathology capabilities, to undertake clinical studies to satisfy the FDA in relation to premarket notification applications for new addressable markets.
- Increase the commercial exposure of the Company specifically in the US, and for general working capital purposes.
The Offer will raise up to AU$16.7m by the issue of more than 209k shares in the capital of the company at an issue price of $0.08 per Share.
Learn more here
View the prospectus here
Review the updated Entitlement Offer timeline here